Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Legal Officer | October 02, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date October 02, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,110 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 5,786 · Balance 14,896 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2026-10-02 · Sale · Disposed 5,786 · Balance 9,110 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2034-02-12 | Direct | 111,251 |
Reported balance
After 2026-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-02 · Exercise / conversion · Disposed 5,786 · Balance 111,251 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 30, 2022 Filed Nov 1, 2022 23:34 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055143 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,013 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2022 Filed Nov 1, 2022 23:34 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055143 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 345 shares of Common Stock acquired by the Reporting Person on August 15, 2022 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:19 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 40,199 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001209191-22-045197 · doc4.xml · derivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,199 Underlying: Common Stock · 40,199 shares Expires 2032-08-08 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning September 9, 2022 until the option is fully vested on August 9, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 21:50 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 712 | $15.67 | $11,157.04 |
DisclosureSEC source: 0001209191-22-043967 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,615 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $15.32 and the highest price at which shares were sold was $16.01. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 30, 2022 Filed Aug 2, 2022 21:50 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043967 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,937 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2022 Filed Aug 2, 2022 21:50 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043967 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2022 Filed May 3, 2022 23:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 660 | $11.75 | $7,755.00 |
DisclosureSEC source: 0001209191-22-026888 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,403 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 30, 2022 Filed May 3, 2022 23:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026888 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,861 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2022 Filed May 3, 2022 23:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026888 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 853 shares of Common Stock acquired by the Reporting Person on February 15, 2022 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 30,785 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004402 · doc4.xml · derivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,785 Underlying: Common Stock · 30,785 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 69,262 | $0.00 Strike: $19.49 | $0.00 |
DisclosureSEC source: 0001209191-22-004402 · doc4.xml · derivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,262 Underlying: Common Stock · 69,262 shares Expires 2032-01-18 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 19, 2022 until the option is fully vested on January 19, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 21:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-22-002849 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,066 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 21:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,200 | $27.14 | $32,568.00 |
DisclosureSEC source: 0001209191-22-002849 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 21:10 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-22-002849 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 21:47 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-069260 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,266 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 21:47 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,200 | $29.04 | $34,848.00 |
DisclosureSEC source: 0001209191-21-069260 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 21:47 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-21-069260 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-064270 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,466 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,200 | $32.38 | $38,856.00 |
DisclosureSEC source: 0001209191-21-064270 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:15 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-21-064270 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 23:25 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-061974 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,666 Underlying: Common Stock · 800 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 23:25 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 800 | $35.25 | $28,200.00 |
DisclosureSEC source: 0001209191-21-061974 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 23:25 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 800 | $1.86 | $1,488.00 |
DisclosureSEC source: 0001209191-21-061974 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-060286 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,466 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,200 | $27.36 | $32,832.00 |
DisclosureSEC source: 0001209191-21-060286 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:43 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-21-060286 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:07 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-055663 · doc4.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,666 Underlying: Common Stock · 2,000 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:07 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 800 | $36.76 | $29,408.00 |
DisclosureSEC source: 0001209191-21-055663 · doc4.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:07 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 500 | $35.77 | $17,884.20 |
DisclosureSEC source: 0001209191-21-055663 · doc4.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $35.64 and the highest price at which shares were sold was $35.90. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:07 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 700 | $35.10 | $24,567.97 |
DisclosureSEC source: 0001209191-21-055663 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,586 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $34.58 and the highest price at which shares were sold was $35.53. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:07 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $1.86 | $3,720.00 |
DisclosureSEC source: 0001209191-21-055663 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-055174 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,666 Underlying: Common Stock · 3,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,200 | $35.25 | $112,800.00 |
DisclosureSEC source: 0001209191-21-055174 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · balance_after: Includes 481 shares of Common Stock acquired by the Reporting Person on August 13, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,200 | $1.86 | $5,952.00 |
DisclosureSEC source: 0001209191-21-055174 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · balance_after: Includes 481 shares of Common Stock acquired by the Reporting Person on August 13, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:21 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-050977 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,866 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:21 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,200 | $29.87 | $35,844.96 |
DisclosureSEC source: 0001209191-21-050977 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $29.37 and the highest price at which shares were sold was $30.33. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:21 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-21-050977 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 21:34 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-047612 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,066 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 21:34 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,200 | $27.00 | $32,400.00 |
DisclosureSEC source: 0001209191-21-047612 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 21:34 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-21-047612 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:11 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-039813 · doc4.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,266 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:11 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 200 | $30.52 | $6,103.00 |
DisclosureSEC source: 0001209191-21-039813 · doc4.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $30.08 and the highest price at which shares were sold was $30.95. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:11 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,000 | $29.18 | $29,179.00 |
DisclosureSEC source: 0001209191-21-039813 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $28.77 and the highest price at which shares were sold was $29.47. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:11 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-21-039813 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 10, 2021 Filed May 11, 2021 23:58 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-031895 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,466 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| May 10, 2021 Filed May 11, 2021 23:58 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,200 | $27.00 | $32,400.00 |
DisclosureSEC source: 0001209191-21-031895 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 10, 2021 Filed May 11, 2021 23:58 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-21-031895 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 22:05 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-029083 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,666 Underlying: Common Stock · 800 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 22:05 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 800 | $35.25 | $28,200.00 |
DisclosureSEC source: 0001209191-21-029083 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 28, 2021 Filed Apr 29, 2021 22:05 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 800 | $1.86 | $1,488.00 |
DisclosureSEC source: 0001209191-21-029083 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.